Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The SELECT study: a warning In 2023, semaglutide was shown to reduce the rates of major adverse cardiovascular events by 20% among persons with a history of atherosclerotic cardiovascular disease and obesity or in persons with overweight and one or more weight-related complications [79]
The systems that matter most for dementia prevention In longevity medicine, the practical question is not whether one therapy is good for the brain. The better question is whether the persons overall biology is moving toward resilience or vulnerability
Activation of GLP-1R signaling promotes M2-like macrophage phenotype while inhibiting M1-like macrophages across various models
This article examines the theoretical mechanisms, reviews available clinical data, and clarifies why GLP-1 agonists are not recommended for rheumatoid arthritis treatment
Bano, D., Zanetti, F., Mende, Y
US$ 20.84
US$ 25.63
US$ 23.58
